Ohsu Knight Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.ohsu.edu/knight-cancer-institute

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

Phase 1
Terminated
Conditions
First Posted Date
2007-08-15
Last Posted Date
2012-07-24
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
6
Registration Number
NCT00516542
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Docetaxel in Treating Patients With Relapsed Prostate Cancer

Phase 2
Terminated
Conditions
First Posted Date
2007-06-05
Last Posted Date
2017-04-28
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
3
Registration Number
NCT00482274
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer

Phase 2
Terminated
Conditions
First Posted Date
2007-04-13
Last Posted Date
2017-04-28
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
21
Registration Number
NCT00459810
Locations
๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

๐Ÿ‡บ๐Ÿ‡ธ

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Phase 2
Terminated
Conditions
First Posted Date
2007-01-29
Last Posted Date
2011-09-02
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
4
Registration Number
NCT00428077
Locations
๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

First Posted Date
2007-01-23
Last Posted Date
2017-05-03
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
60
Registration Number
NCT00425386
Locations
๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Southern California, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Salem Hospital, Salem, Oregon, United States

and more 1 locations

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

First Posted Date
2006-12-28
Last Posted Date
2017-09-27
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
1
Registration Number
NCT00416884
Locations
๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

First Posted Date
2006-09-28
Last Posted Date
2017-06-12
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
54
Registration Number
NCT00381862
Locations
๐Ÿ‡บ๐Ÿ‡ธ

St. Josephs/Cander Hospital, Savannah, Georgia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Kaiser Permanente, Hilo, Hawaii, United States

๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

and more 3 locations

Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

First Posted Date
2006-06-12
Last Posted Date
2017-05-09
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
54
Registration Number
NCT00335478
Locations
๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-05-31
Last Posted Date
2017-10-26
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
23
Registration Number
NCT00331409
Locations
๐Ÿ‡บ๐Ÿ‡ธ

OHSU Knight Cancer Institute, Portland, Oregon, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath